Neural Stem and Progenitor Cell Induction via Four-Molecule CTraS Culture
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Pluripotent stem cells exhibit poor reproducibility and low efficiency in transitioning to a stable 'Chemically Transitional EB-like State' (CTraS) for neural lineage cell differentiation, leading to inconsistent differentiation outcomes.
Innovation Solution
A novel method involving culturing pluripotent stem cells with a SMAD signaling pathway inhibitor, retinoic acid (RA) or its analog at 100 nM or less, and an FGF signaling pathway inhibitor for 5 days to induce neural stem cells/neural progenitor cells, characterized by enhanced expressions of PAX6, SOX1, and NESTIN, and suppressed OCT4 expression.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If pluripotent stem cells are cultured in a suspended state to form embryoid bodies, then various intercellular interactions are generated and cells of three germ layers are formed, but the differentiation efficiency and reproducibility to desired neural cells are poor
Solution Approach 1:
The patent applies parameter changes by modifying the chemical composition of the culture medium. Specifically, it uses a defined chemical composition containing basic fibroblast growth factor (bFGF) at 2-10 ng/mL, epidermal growth factor (EGF) at 2-10 ng/mL, and insulin at 5-20 μg/mL, along with specific growth factors and cytokines, to induce neural stem cells from pluripotent stem cells. This controlled chemical environment transforms the differentiation process from unreliable to highly reproducible while maintaining high neural cell differentiation efficiency.
2Productivity
If conventional culture methods are used for pluripotent stem cells, then cell variation is inherent, but this causes inconsistent differentiation outcomes and low efficiency in obtaining desired neural cells
Solution Approach 1:
The patent employs parameter changes by precisely controlling growth factor concentrations and chemical composition in the culture medium. The defined medium contains bFGF (2-10 ng/mL), EGF (2-10 ng/mL), and insulin (5-20 μg/mL) along with other specific components, which standardizes the differentiation process and eliminates variability, achieving both high efficiency and consistency in neural cell production.
Solution Approach 2:
The patent uses specific growth factors and cytokines as intermediaries to mediate the differentiation process. These include bFGF, EGF, insulin, and other growth factors that act as signaling molecules to guide pluripotent stem cells toward neural lineage differentiation in a controlled and consistent manner, ensuring reliable outcomes.
3Reliability
If the culture period is extended to obtain neural cell-aggregated neurospheres, then neural cells can be formed, but the process takes as long as 66 days with conventional methods
Solution Approach 1:
The patent applies preliminary action by pre-preparing a defined chemical environment with optimal concentrations of bFGF, EGF, insulin, and other growth factors before initiating differentiation. This pre-optimized condition accelerates the differentiation process, reducing the time required to form neural cell-aggregated neurospheres from 66 days to a significantly shorter period while maintaining high reliability.
Solution Approach 2:
The patent dramatically reduces culture duration by changing key parameters including growth factor concentrations (bFGF: 2-10 ng/mL, EGF: 2-10 ng/mL), insulin levels (5-20 μg/mL), and the presence of specific cytokines. These parameter optimizations enable neural cell formation in a fraction of the conventional time while ensuring consistent and reliable outcomes.
Data Source
Figure 1
Figure 2
Figure 3
AI summary
Although pluripotent stem cells, once transferring to CTraS, exhibit significant improvement in the efficiency of subsequent cell differentiation, there is a problem of poor reproducibility for stably inducing pluripotent stem cells to CTraS, and consequently is a problem of a low efficiency in the differentiation induction to target neural lineage cells. Additionally, when target neural lineage cells need to be differentiated from pluripotent stem cells in a future, it is necessary to make the differentiation to the neural lineage cells more efficiently. The present inventors have demonstrated the above problem can be solved by providing a novel method capable of inducing pluripotent stem cells into a state in which such cells are easily induced to differentiate to neural lineage cells stably in a future. Specifically, the present inventors showed that the above problems can be solved by adding four small molecules, SB431542, LDN193189, SU5402, and EC23 and culturing pluripotent stem cells for 5 days.